Project
A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy
Automatically Closed · 2012 until 2013
Siano Marco, Früh Martin
Type
Clinical Studies
Range
Monocentric project at KSSG
Units
Status
Automatically Closed
Start Date
2012
End Date
2013
Financing
Industry
Study Design
Phase III
Keywords
PF-00299804, Erlotinib, Bronchialkarzinom
Homepage
Partner
-
Additional Information
-
Brief description/objective
Erwartung, dass die Behandlung mit Dacomitinib einem/einer Patienten (-innnen) eine längere Progressions-freie Dauer bietet.